Belcaro G, Marelli C, Pomante P, Laurora G, Cesarone M R, Ricci A, Girardello R, Barsotti A
Microcirculation Laboratory, G.D'Annunzio University, Chieti, Italy.
Angiology. 1992 Oct;43(10):793-800. doi: 10.1177/000331979204301001.
Skin microcirculation was evaluated in 117 patients with diabetic microangiopathy over a period of six months. They were divided into two groups. Group 1 (64 patients) was treated with oral defibrotide, a new profibrinolytic drug, in association with diet and oral antidiabetic drugs. Group 2 (53 patients) was treated only with diet and antidiabetic agents. The microcirculation was studied by means of laser-Doppler flowmetry transcutaneous partial pressure of oxygen and carbon dioxide pressure measurements, and evaluation of capillary filtration. After six months, patients in group 1 improved their microcirculatory parameters in association with an improvement in signs and symptoms. Moreover, 30 patients in group 1 and 36 in group 2 were followed up for eighteen months, and the authors observed that the deterioration of the microcirculatory parameters was significantly slowed in diabetics treated with defibrotide. A decrease in plasma fibrinogen during defibrotide treatment was observed in all treated patients in association with an increased fibrinolytic activity. In conclusion, it appears that defibrotide, enhancing fibrinolysis, improved the microcirculation in diabetics, preventing further, progressive deterioration.
对117例糖尿病微血管病变患者进行了为期6个月的皮肤微循环评估。他们被分为两组。第一组（64例患者）接受口服去纤苷（一种新型纤溶药物）治疗，并结合饮食和口服降糖药。第二组（53例患者）仅接受饮食和降糖药物治疗。通过激光多普勒血流仪、经皮氧分压和二氧化碳分压测量以及毛细血管滤过评估来研究微循环。6个月后，第一组患者的微循环参数有所改善，同时体征和症状也有所改善。此外，对第一组的30例患者和第二组的36例患者进行了18个月的随访，作者观察到接受去纤苷治疗的糖尿病患者微循环参数的恶化明显减缓。在所有接受治疗的患者中，观察到去纤苷治疗期间血浆纤维蛋白原减少，同时纤溶活性增加。总之，去纤苷似乎通过增强纤溶作用改善了糖尿病患者的微循环，防止了进一步的进行性恶化。
